This is a preview of subscription content, access via your institution
Access options
Subscribe to this journal
Receive 12 digital issues and online access to articles
$119.00 per year
only $9.92 per issue
Buy this article
- Purchase on Springer Link
- Instant access to full article PDF
Prices may be subject to local taxes which are calculated during checkout
References
Beevers DG . Beta-blockers for hypertension: time to call a halt? J Hum Hypertens 1998; 12: 807–810
ALLHAT Collaborative Research Group. Major cardiovascular events in hypertensive patients randomized to doxazosin vs chlorthalidone: the antihypertensive and lipid-lowering treatment to prevent heart attack trial (ALLHAT) JAMA 2000; 283: 1967–1975
Pahor M et al. Health outcomes associated with calcium antagonists compared with other first-line antihypertensive therapies: a meta-analysis of randomised controlled trials Lancet 2000; 356: 1949–1954
Hansson L et al. Effect of angiotensin-converting-enzyme inhibition compared with conventional therapy on cardiovascular morbidity and mortality in hypertension: the Captopril Prevention Project (CAPPP) randomised trial Lancet 1999; 353: 611–616
Hansson L et al. Randomised trial of effects of calcium antagonists compared with diuretics and beta-blockers on cardiovascular morbidity and mortality in hypertension: the Nordic Diltiazem (NORDIL) study Lancet 2000; 356: 359–365
Lip GYH, Beevers DG . Calcium channel blockers in hypertension: the debate reawakens J Hum Hypertens 2001; 15: 85–87
Beevers DG, Lip GYH . The protective effect of blocking angiotensin in both type I and type II diabetics with nephropathy J Hum Hypertens 2001; 15: 837–839
Dahlöf B et al. Cardiovascular morbidity and mortality in the Losartan Intervention For Endpoint reduction in hypertension study (LIFE): a randomized trial against atenolol Lancet 2002; 359: 995–1003
Lindholm LH et al. Cardiovascular morbidity and mortality in patients with diabetes in the Losartan Intervention For Endpoint reduction in hypertension study (LIFE): a randomized trial against atenolol Lancet 2002; 359: 1004–1010
Yusuf S et al. Effects of an angiotensin-converting-enzyme inhibitor, Ramipril on cardiovascular events in high-risk patients. The Heart Outcomes Prevention Evaluation Study Investigators N Engl J Med 2000; 342: 145–153
Sleight P et al. Blood-pressure reduction and cardiovascular risk in HOPE study Lancet 2001; 358: 2130–2131
Svensson P et al. Comparative effects of ramipril on ambulatory and office blood pressures. A HOPE substudy Hypertension 2001; 38: e28–e32
PROGRESS Collaborative Group. Randomised trial of a perindopril-based blood-pressure-lowering regimen among 6,105 individuals with previous stroke or transient ischaemic attack Lancet 2001; 358: 1033–1041
Lip GYH, Beevers DG . ACE inhibitors in vascular disease: some PROGRESS, more HOPE J Hum Hypertens 2001; 15: 833–835
Felmeden DC, Lip GYH . The renin-angiotensin-aldosterone system and fibrinolysis J Renin Angiotensin Aldosterone Syst 2000; 1: 240–244
Li-Saw-Hee FL, Beevers DG, Lip GYH . Effect of antihypertensive therapy using enalapril or losartan on haemostatic markers in essential hypertension: a pilot prospective randomised double-blind parallel group trial Int J Cardiol 2001; 78: 241–246
Le Noble FAC, Stassen FRM, Hacking WJG, Struijker Boudier HAJ . Angiogenesis and hypertension J Hypertens 1998; 16: 1563–1572
Belgore FM et al. Plasma levels of vascular endothelial growth factor and its soluble receptor (SFlt-1) in essential hypertension Am J Cardiol 2001; 87: 805–807
Ward HJ . Uric acid as an independent risk factor in the treatment of hypertension Lancet 1998; 352: 670–671
Lip GYH, Edmunds E, Beevers DG . Should patients with hypertension receive antithrombotic therapy? J Intern Med 2001; 249: 205–214
Chin BS, Lip GYH . Blockade of the renin-angiotensin-aldosterone system with combination angiotensin receptor antagonist and ACE inhibitor therapy: observations from Val-HeFT and CALM J Hum Hypertens 2001; 15: 89–92
Author information
Authors and Affiliations
Corresponding author
Rights and permissions
About this article
Cite this article
Lip, G. Losartan and the meaning of LIFE. J Hum Hypertens 16, 289–291 (2002). https://doi.org/10.1038/sj.jhh.1001425
Published:
Issue Date:
DOI: https://doi.org/10.1038/sj.jhh.1001425